Monoamine oxidase B inhibitors. Current status and future potential

CNS Drugs

Volumn 6, Issue 3, 1996, Pages 217-236

  Bentué Ferrer, Danièle ^a   Ménard, Gaëlle ^a   Allain, Hervé ^a,b  

^a UNIVERSITÉ DE RENNES 1   (France)

^b Inst de Rech Contre le Cancer IRCC   (France)

Author keywords

[No Author keywords available]

Indexed keywords

2 (3,4 DIMETHOXYPHENYL) 3 FLUOROALLYLAMINE; LAZABEMIDE; MILACEMIDE; MOFEGILINE; MONOAMINE OXIDASE INHIBITOR; N (2 PROPYNYL) 1 INDANAMINE; SELEGILINE;

AGING; ALZHEIMER DISEASE; DEPRESSION; DYSKINESIA; HUMAN; NAUSEA; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW;

EID: 0029845388     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-199606030-00005     Document Type: Review

References (189)

1. Hare MLC. Tyramine oxidase new enzyme in liver. Biochem J 1928; 22: 968-79
2. Zeller EA. Uber den enzymatischen abban von Histamine und Diamine. Helv Chim Acta 1938; 21: 880-90
3. Johnston JP. Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem Pharmacol 1968; 17: 1285-97
4. Fowler CJ, Callingham BA, Mantle TJ, et al. Monoamine oxidase A and B: a useful concept. Biochem Pharmacol 1978; 27: 97-101
5. Bach AW, Lan NC, Johnson DL. cDNA cloning of human liver monoamine oxidase A and B: molecular basis of differences in enzymatic properties. Proc Natl Acad Sci USA 1988; 85: 4934-8
6. Strolin-Benedetti M, Dostert P. Monoamine oxidase: from physiology and pathophysiology to the design and clinical application of reversible inhibitors. Adv Drug Res 1992; 23: 65-125
7. Allain H. Neuromédiateurs et pharmacologie des monoamines oxydases. Lett Pharmacol 1995; 9: 3-7
8. Yu PH, Boulton AA. Clinical pharmacology of MAO-B inhibitors. In: Kennedy SH, editor. Progress in psychiatry: clinical advances in monoamine oxidase inhibitor therapies. Washington, DC: American Psychiatric Press Inc., 1994; 3: 61-82
9. Le Crubier Y. Risk-benefit assessment of newer versus older monoamine oxidase inhibitors. Drug Saf 1994; 10: 292-300
10. Knoll J, Magyar K. Some puzzling pharmacological effects of monoamine oxidase inhibitors. Adv Biochem Psychopharmacol 1972; 5: 393-408
11. Gerlach M, Riederer P, Youdim MBH. The molecular pharmacology of l-deprenyl. Eur J Pharmacol 1992; 226: 97-108
12. Allain H, Pollak P, Neukirch HC. Symptomatic effect of selegiline in de novo parkinsonian patients. Mov Disord 1993; 8 Suppl. 1: S36-40
13. Heikkila RE, Manzino L, Cabbat FS, et al. Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6 tetrahydropyridine by monoamine oxidase inhibitors. Nature 1984; 311: 467-9
14. Markey SP, Johannesen JN, Chinen CC, et al. Interneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism. Nature 1984; 311: 465-7
15. Delumeau JC, Bentué-Ferrer D, Gandon JM, et al. Monoamine-oxidase inhibitors, cognitive functions, and neurodegenerative diseases. J Neural Transm Gen Sect 1994; 41 Suppl. 1: 259-66
16. Kanazawa I. Short review on monoamine oxidase and its inhibitors. Eur Neurol 1994; 34 Suppl. 3: 36-9
17. Youdim MBH, Finberg JPM. Pharmacological actions of l-deprenyl (selegiline) and other selective monoamine oxidase B inhibitors. Clin Pharmacol Ther 1994; 56: 725-33
18. Leigh PN. Pathogenic mechanisms in amyotrophic lateral sclerosis and other motor neuron disorders. In: Calne DB, Horowski R, Mizuno Y, et al., editors. Advances in research on neurodegeneration. Boston: Birkhauser, 1993; 13: 163-82
19. Yu PH, Boulton AA. Irreversible inhibition of monoamine oxidase by some components of cigarette smoke. Life Sci 1987; 41: 675-82
20. Kando JC, Kalunian DA. Focus on selegiline: a selective monoamine oxidase type B inhibitor. Hosp Formul 1990; 25: 849-58
21. Allain H, Bentué-Ferrer D. Central neurotransmission in elderly. In: Macieira-Coelho A, editor. Molecular basis of aging. Ann Arbor: CRC Press, 1995: 511-25
22. Pall HS, Williams AC, Waring RH, et al. Motor neuron disease as manifestation of pesticide toxicity [letter]. Lancet 1987; II: 685
23. Bodagh IYO, Robertson DRC. A risk-benefit assessment of drugs used in the management of Parkinson's disease. Drug Saf 1994; 11: 94-103
24. Olanow CW, Calne D. Does selegiline monotherapy in Parkinson's disease act by symptomatic or protective mechanisms? Neurology 1991; 42 Suppl. 4: 13-26
25. Murphy DL, Sunderland T. MAOIs in the neurodegenerative disorders. In: Kennedy SH, editor. Progress in psychiatry: clinical advances in monoamine oxidase inhibitor therapies. Washington, DC: American Psychiatric Press Inc., 1994; 3: 61-82
26. Saura J, Richards JG, Mahy N. Differential age-related changes of MAO-A and MAO-B in mouse brain and peripheral organs. Neurobiol Aging 1994; 15: 399-408
27. Fowler CJ, Wiberg A, Oreland L. The effect of age on the activity and molecular properties of human brain monoamine oxidase. J Neural Transm Park Dis Dement Sect 1980; 49: 1-20
28. Oreland L, Gottfries CG. Brain and monoamine oxidase in aging and in dementia of the Alzheimer's type. Prog Neuropsychopharmacol Biol Psychiatry 1986; 10: 533-40
29. Saura J, Luque JM, Cesura AM, et al. Increased monoamine oxidase B activity in plaque-associated astrocytes of Alzheimer brains revealed by quantitative enzyme radioautography. Neuroscience 1994; 62: 15-30
30. Kalir A, Sabbagh A, Youdim MBH. Selective acetylenic 'suicide' and reversible inhibitors of monoamine oxidase types A and B. Br J Pharmacol 1981; 73: 55-64
31. Fowler JS, Volkow ND, Logan J, et al. Slow recovery of human brain MAO-B after L deprenyl (selegiline) withdrawal. Synapse 1994; 18: 86-93
32. Heinonen EH, Anttila M, Nyman L, et al. Desmethylselegiline, a metabolite of selegiline, is an irreversible inhibitor of MAO-B in human subjects [abstract]. Neurology 1993; 43 Suppl. 2: A156
33. Hinze C, Harland D, Zreika M, et al. A double-blind, placebo-controlled study of the tolerability and effects on platelet MAO-B activity of single oral doses of MDL 72,974 A in normal volunteers. J Neural Transm Suppl. 1990; 32: 203-9
34. Fowler JS, Volkow ND, Logan J, et al. Monoamine oxidase B (MAO B) inhibitor therapy in Parkinson's disease: the degree and reversibility of human brain MAO-B inhibition by Ro 19 6327. Neurology 1993; 43: 1984-92
35. O'Brien EM, Tipton KF, McCrodden J, et al. The interactions of milacemide with monoamine oxidase. Biochem Pharmacol 1994; 47: 617-23
36. Cesura AM, Muggli-Maniglio D, Lang G, et al. Monoamine oxidase inhibition by moclobemide and 2-amino-ethyl carboxamide derivatives: mode of action and kinetic characteristics. J Neural Transm Suppl. 1990; 32: 165-70
37. Silverman RB. Mechanism-based enzyme inactivation chemistry and enzymology. Vol. 1. Boca Raton: CRC Press, 1988
38. Grimsby J, Zentner M, Shih JC. Identification of a region important for human monoamine oxidase B substrate and inhibitor selectivity. Life Sci 1996; 58: 777-87
39. Henriot S, Kuhn C, Kettler R, et al. Lazabemide (Ro 19-6327). a reversible and highly sensitive MAO-B inhibitor: preclinical and clinical findings. J Neural Transm Suppl. 1994; 41: 321-5
40. Chrisp P, Mammen GJ, Sorkin EM. Selegiline: a review of its pharmacology, symptomatic benefits and protective potential in Parkinson's disease. Drugs Aging 1991; 1: 228-48
41. Bench CJ, Price GW, Lammertsma AA. Measurement of human cerebral monoamine oxidase type B (MAO-B) activity with positron emission tomography (PET): a dose ranging study with the reversible inhibitor Ro 19-6327. Eur J Clin Pharmacol 1991; 40: 169-73
42. Dulery BD, Schoun J, Zreika M, et al. Pharmacokinetics of and monoamine oxidase B inhibition by (E)-4-fluoro-b-fluoromethylene benzene butanamine in man. Arzneimittelforschung 1993; 43: 297-302
43. Elsworth JD, Glover V, Reynolds GP, et al. Deprenyl administration in man: a selective MAO-B inhibitor without the 'cheese' effect. Psychopharmacologia 1978; 57: 33-8
44. Birkmayer W, Riederer P, Youdim MBH. Potentiation of the anti-akinetic effect of L-dopa by an inhibitor of MAO-B, deprenyl. J Neural Transm 1975; 36: 303-26
45. Da Prada M, Kettler R, Keller HH, et al. Reversible enzyme-activated monoamine oxidase inhibitors: new advances. Pharmacol Res Commun 1988; 20 Suppl. 4: 21-33
46. Sunderland T, Mueller EA, Cohen RM, et al. Tyramine pressor sensitivity changes during deprenyl treatment. Psychopharmacology 1985; 86: 432-7
47. Huebert ND, Dulery BD, Schoun J, et al. Kinetics and metabolism of p-tyramine during monoamine oxidase inhibition by mofegiline. Clin Pharmacol Ther 1994; 56: 537-42
48. Hinze C, Kaschube M, Hardenberg J. Pharmacodynamics of MDL 72974 A: absence of effect on the pressor response to oral tyramine. J Neural Transm Suppl. 1994; 41: 371-5
49. Janssens De Varebeke P, Pauwels G, et al. The novel neuropsychotropic agent milacemide is a specific enzyme-activated inhibitor of brain monoamine oxidase. Br J Neurochem 1989; 53: 1109-16
50. Finberg JPM, Tenne M, Youdim MBH. Tyramine antagonistic properties of AGN 1135. an irreversible inhibitor of monoamine oxidase type B. Br J Pharmacol 1981; 73: 65-74
51. Paterson IA, Jurio AV, Boulton AA. 2-phenylethylamine: a modulator of catecholamine transmission in the mammalian central nervous system. J Neurochem 1990; 55: 1827-37
52. Boulton AA. Phenylethylaminergic modulation of catecholaminergic neurotransmission. Prog Neuropharmacol Biol Psychiatry 1991; 15: 139-56
53. Faucheux B, Nieoullon A. Le L-déprényl: effets symptomatiques, neuroprotecteurs et neurotrophiques potentiels dans la maladie de Parkinson? Lett Pharmacol 1993; 7 Suppl.: 12-7
54. Huebert ND, Schwach V, Richter G, et al. The measurement of β-phenylethylamine in human plasma and rat brain. Anal Biochem 1994; 221: 42-7
55. Berry MD, Scarr E, Zhu MY, et al. The effects of administration of monoamine oxidase-B inhibitors on rat striatal neurone responses to dopamine. Br J Pharmacol 1994; 113: 1159-66
56. Ortmann R, Schaub M, Felner A, et al. Phenylethylamine-induced stereotypies in the rat: a behavioral test system for assessment of MAO-B inhibitors. Psychopharmacology 1984; 84: 22-7
57. Li XM, Juorio AV, Paterson IA, et al. Specific irreversible monoamine oxidase B inhibitors stimulate gene expression of aromatic L-amino acid decarboxylase in PC 12 cells. J Neurochem 1992; 59: 2324-7
58. Stoltz M, Reynolds D, Elkins L, et al. Pharmacokinetics and pharmacodynamics of the monoamine oxidase B inhibitor mofegiline assessed during a phase I dose tolerance trial. Clin Pharmacol Ther 1995; 58: 342-53
59. Faucheux B, Nieoullon A. Actualités sur les monoamines oxydases (MAO) et le stress oxydatif dans la maladie de Parkinson: vers la mise au point de nouveaux traitements à visée étiologique? Lett Pharmacol 1993; 7 Suppl.: 4-11
60. Olanow CW. A rationale for monoamine oxidase inhibition as neuroprotective therapy for Parkinson's disease. Mov Disord 1993; 8 Suppl. 1: 51-7
61. Allain H. La dopamine: neurotoxique ou neurotrophique? Lett Pharmacol 1995; 9 Suppl. 7: 20-3
62. Nadi M, Takahashi T, Parvez H, et al. N-methyl-iso-quinolinium ion as an inhibitor of tyrosine hydroxylase, aromatic L-amino acid decarboxylase and monoamine-oxidase. Neurochem Int 1989; 15: 315-20
63. Cohen G, Spina MB. Deprenyl suppresses the oxidant stress associated with increased dopamine turnover. Ann Neurol 1989; 26: 689-90
64. Knoll J. The striatal dopamine dependency of life span in male rats, longevity study with (-) deprenyl. Mech Ageing Dev 1988; 46: 237-62
65. Carrillo MC, Kanai S, Nokubo M, et al. (-) Deprenyl induces activities of both superoxide dismutase and catalase but not of glutathione peroxidase in the striatum of young male rats. Life Sci 1991; 48: 517-21
66. Clow A, Hussain T, Glover V, et al. (-) Deprenyl can induce soluble superoxide dismutase in rat striata. J Neural Transm Gen Sect 1991; 86: 77-80
67. Lai CT, Zuo DM, Yu PH. Is brain superoxide dismutase activity increased following chronic treatment with l-deprenyl? J Neural Transm Suppl. 1994; 41: 221-9
68. Lange KW, Riederer P, Youdim MBH. Biochemical actions of l-deprenyl (selegiline). Clin Pharmacol Ther 1994; 56: 734-41
69. Baronti F, Davis TL, Boldry RC, et al. Deprenyl effects on levodopa pharmacodynamics, mood, and free radical scavenging. Neurology 1992; 42: 541-4
70. Parkinson Study Group. Effect of deprenyl and tocopherol on the progression of disability in early Parkinson's disease. N Engl J Med 1993; 328: 176-83
71. Suzuki T, Akaike N, Ueno K, et al. MAO inhibitors clorgyline and lazabemide prevent hydroxyl radical generation caused by brain ischemia reperfusion in mice. Pharmacology 1995; 50: 357-62
72. Clow A, Freestone C, Lewis E, et al. The effect of pergolide and MDL 72974 on rat brain CuZn superoxide dismutase. Neurosci Lett 1993; 164: 41-3
73. Langston JW, Ballard PA, Tetrud JW, et al. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983; 219: 979-80
74. Tetrud JW, Langston JW. The effect of deprenyl (selegiline) on the natural history of Parkinson's disease. Science 1989; 245: 519-22
75. + to dopaminergic neurone of the rat substantia nigra. Eur J Pharmacol 1986; 12: 171-4
76. Hantraye P, Peschanski M. Le déprényl, traitement de premiere intention dans la maladie de Parkinson. Med Sci 1989; 9: 685-6
77. Ballard PA, Tetrud JW, Langston JW. Permanent human parkinsonism due to 1-methyl-4-phenyl 1,2,3,6 tetrahydropyridine: seven cases. Neurology 1985; 35: 949-56
78. Tipton KFT. What is it that l-deprenyl (selegiline) might do? Clin Pharmacol Ther 1994; 56: 781-96
79. Cohen G, Pasik P, Cohen B, et al. Pargyline and selegiline prevent the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6 tetrahydropyridine (MPTP) in monkeys. Eur J Pharmacol 1984; 106: 209-10
80. Tatton WG, Greenwood CE. Rescue of dying neurons: a new action for deprenyl in MPTP parkinsonism. J Neurosci Res 1991; 30: 666-72
81. Haefely WE, Kettler R, Keller HH, et al. Ro 19-6327, a reversible and highly selective monoamine oxidase B inhibitor: a novel tool to explore the MAO-B function in humans. Adv Neurol 1990; 53: 505-12
82. Heikkila RE, Duvoisin RC, Finberg JPM. Prevention of MPTP-induced neurotoxicity by AGN-1133 and AGN-1135, selective inhibitors of monoamine oxidase-B. Eur J Pharmacol 1985; 116: 313-7
83. Gibson CJ. Inhibition of MAO-B, but not MAO-A, blocks DSP-4 toxicity on central NE neurons. Eur J Pharmacol 1987; 141: 135-8
84. Zhang X, Yu PH. Depletion of NOS activity in the rat dentate gyrus neurons by DSP-4 and protection by deprenyl. Brain Res Bull 1995; 38: 307-11
85. Finnegan KT, Skratt JJ, Irwin I, et al. Protection against DSP-4 induced neurotoxicity by deprenyl is not related to its inhibition of MAO-B. Eur J Pharmacol 1990; 184: 119-26
86. Gaal J, Szekacs G, Szebeni G, et al. Neurotoxicity of DSP-4 on pigs and prevention of its neurotoxicity by deprenyl [abstract]. 6th Amine Oxidase Workshop and 5th Trace Amine Conference: 1994 Aug 18-23; Galway, Ireland, B09
87. Magyar K, Legyel J, Gaal J. Neuroprotective effect of (-) deprenyl against DSP-4 toxicity in rats. In: 6th Amine Oxidase Workshop and 5th Trace Amine Conference: 1994 Aug 18-23; Galway, Ireland, L22
88. Hallman H, Jonsson G. Pharmacological modifications of the neurotoxic action of the noradrenaline neurotoxin DSP-4 on central noradrenaline neurons. Eur J Pharmacol 1984; 103: 269-78
89. Magyar K. Behaviour of (-)deprenyl and its analogues. J Neural Transm Suppl. 1994; 41: 167-75
90. Knoll J. The pharmacology of selegiline (L-deprenyl): new aspects. Acta Neurol Scand 1989; 126: 23-33
91. Benmansour S, Brunswick DJ. The MAO-B inhibitor deprenyl, but not the MAO-A inhibitor clorgyline, potentiates the neurotoxicity of p-chloroamphetamine. Brain Res 1994; 650: 305-12
92. Garrick NA, Murphy DL. Species differences in the deamination of dopamine and other substrates for monoamine oxidase in brain. Psychopharmacology 1980; 72: 27-33
93. Glue P, Coupland N, Nutt DJ. Pharmacological basis for the therapeutic activity of MAOIs. In: Kennedy SH, editor. Progress in psychiatry: clinical advances in monoamine oxidase inhibitor therapies. Washington, DC: American Psychiatric Press Inc., 1994; 61-82
94. O'Regan D, Kwok RPS, Bailey BA, et al. A behavioral and neurochemical analysis of chronic and selective monoamine oxidase inhibition. Psychopharmacology 1987; 92: 42-7
95. Butcher SP, Fairbrother JS, Kelly JS, et al. Effects of selective monoamine oxidase inhibitors on the in vivo release and metabolism of dopamine in the rat striatum. J Neurochem 1990; 55: 981-8
96. Finberg JP, Wang J, Goldstein DS, et al. Influence of selective inhibition of monoamine oxidase A or B on striatal metabolism of L-DOPA in hemiparkinsonian rats. J Neurochem 1995; 65: 1213-20
97. Wachtel SR, Abercrombie ED. L-3,4-dihydroxyphenylalanine-induced dopamine release in the striatum of intact and 6-hydroxydopamine treated rats: differential effects of monoamine oxidase A and B inhibitors. J Neurochem 1994; 63: 108-17
98. Nomoto M, Fukada T. A selective MAO-B inhibitor RO 19-6327 potentiates the effects of levodopa on parkinsonism induced by MPTP in the common marmoset. Neuropharmacology 1993; 32: 473-7
99. Strolin-Benedetti M, Kettler R, Marrari P, et al. The effects of lifelong treatment with MAO inhibitors on amino acid levels in rat brain. J Neural Transm Park Dis Dement Sect 1990; 2: 239-48
100. Colzi A, D'Agostini F, Kettler R, et al. Effect of selective and reversible MAO inhibitors on dopamine outflow in rat striatum: a microdialysis study. J Neural Transm Suppl. 1990; 32: 79-84
101. Da Prada M, Kettler R, Keller HH. From moclobemide to Ro 19-6327 and Ro 41-1049: the development of a new class of reversible, selective MAO-A and MAO-B inhibitors. J Neural Transm Suppl. 1990; 29: 279-92
102. Semba J, Doheny M, Patsalos PN, et al. Effect of milacemide on extracellular and tissue concentrations of dopamine and 5-hydroxytryptamine in rat frontal cortex. Br J Pharmacol 1992; 105: 59-62
103. Semba J, Patsalos PN. Milacemide effects on the temporal inter-relationship of amino acids and monoamine metabolites in rat cerebrospinal fluid. Eur J Pharmacol 1993; 230: 321-6
104. Knoll J. The pharmacological basis of the beneficial effects of (-) deprenyl (selegiline) in Parkinson's and Alzheimer's diseases. J Neural Transm Suppl. 1993; 40: 69-91
105. Bondiolotti GP, Galva MD, Villa F, et al. In vitro effects on monoamine uptake and release by the reversible monoamine oxidase-B inhibitors lazabemide and N-(2-aminoethyl)-p-chlorobenzamide: a comparison with L-deprenyl. Biochem Pharmacol 1995; 50: 97-102
106. Tatton WG, Ansari K, Ju W, et al. Selegiline induces 'trophic-like' rescue of dying neurons without MAO inhibition. Adv Exp Med Biol 1995; 363: 15-6
107. Salo PT, Tatton WG. Deprenyl reduces the death of motoneurons caused by axotomy. J Neurosci Res 1992; 31: 394-400
108. Zhang F, Richardsson PM, Holland DP, et al. CNTF or (-)-deprenyl in immature rats: survival of axotomized facial motoneurons and weight loss. J Neurosci Res 1995; 40 (4): 564-70
109. Ansari KS, Yu PH, Kruck TPA, et al. Rescue of axotomized immature rat facial motoneurons by R (-) deprenyl: stereo-specificity and independence from monoamine oxidase inhibition. J Neurosci 1993; 13: 4042-53
110. Seniuk NA, Henderson JT, Tatton WG. Increased CNTF gene expression in process-bearing astrocytes following injury is augmented by R(-)-deprenyl. J Neurosci Res 1994; 37: 278-86
111. Buys YM, Trope GE, Tatton WG (-)-Deprenyl increases the survival of rat retinal ganglion cells after optic nerve crush. Curr Eye Res 1995; 14: 119-26
112. Youdim MBH, Riederer P. The relevance of glial monoamine oxidase-B and polyamines to the action of selegiline in Parkinson's disease. Mov Disord 1993; 8 Suppl. 1: S8-13
113. Robin DW. Selegiline in the treatment of Parkinson's disease. Am J Med Sci 1991; 302: 392-5
114. Kando JC, Kalunian DA. Focus on selegiline: a selective monoamine oxidase type B inhibitor. Hosp Formul 1990; 25: 849-58
115. Holford NH, Guentert TW, Dingemanse J, et al. Pharmacodynamics of lazabemide, a reversible and selective inhibitor of monoamine oxidase B. Br J Clin Pharmacol 1994; 37: 553-7
116. Riederer P, Youdim MBH, Rausch WD, et al. On the mode of action of L-deprenyl in the human central nervous system. J Neural Transm 1978; 43: 217-26
117. Reynolds GP, Elsworth JD, Blau K, et al. Deprenyl is metabolised to methamphetamine and amphetamine in man. Br J Clin Pharmacol 1978; 6: 524-44
118. Petit H, Allain H, Vermersch P. La maladie de Parkinson: clinique et thérapeutique. Paris: Masson, 1994
119. Dow J, Piriou F, Wolf E, et al. Novel carbamate metabolites of mofegiline, a primary amine monoamine oxidase B inhibitor, in dogs and humans. Drug Metab Dispos 1994; 22: 738-49
120. Semba J, Curzon G, Patsalos P. Antiepileptic drug pharmacokinetics and neuropharmacokinetics in individual rats by repetitive withdrawal of blood and cerebrospinal fluid: milacemide. Br J Pharmacol 1993; 108: 1117-24
121. Allain H, Bellissant E. Analyse des résultats de l'essai DATATOP. Lett Pharmacol 1993; 7: 82-5
122. Allain H, Bentué-Ferrer D, Belliard S, et al. Pharmacology of Alzheimer's disease. Prog Med Chem. In press
123. Allain H, Lieury A, Gandon JM. Psychopharmacology of memory components. Hum Psychopharmacology 1993; 4: 143-64
124. Allain H, Bernard PM, Dartigues JF, et al. Point de vue sur la méthodologie des essais de médicaments à visée cognitive chez les sujets âgés. Encephale 1994; XX; 725-39
125. Lewitt PA, Segel SA, Mistura KL, et al. Symptomatic anti-parkinsonian effects of monoamine oxidase-B inhibition: comparison of selegiline and lazabemide. Clin Neuropharmacol 1993; 16: 332-7
126. Parkinson Study Group. A controlled trial of lazabemide (RO 19 6327) in untreated Parkinson's disease. Ann Neurol 1993; 33: 350-6
127. Myllyla VV, Sotaniemi KA, Aasly J, et al. An open multicenter study of the efficacy of MDL 72974A a monoamine oxidase type B (MAO-B) inhibitor, in Parkinson's disease. Adv Neurol 1993; 60: 676-80
128. Palfreyman MG, McDonald IA, Zreika M, et al. MDL 72974 A: a selective MAO-B inhibitor with potential for treatment of Parkinson's disease. J Neural Transm Suppl. 1993; 40: 101-11
129. Mizuno Y, Mori H, Kondo T. Practical guidelines for the drug treatment of Parkinson's disease. CNS Drugs 1994; 1: 410-26
130. Hubble JP, Waters CH, Koller WC. Deprenyl dosing considerations [letter]. Ann Neurol 1991; 30: 258
131. Scott A, Lewitt PA, Mistura KL. Cross-over trial of RO-19-6327 and selegiline in otherwise untreated Parkinson's disease [abstract]. Neurology 1993; 43: A333
132. Fazzini E, Chin L, Choi J, et al. Significant reversible symptomatic effect of RO-19-6327 in Parkinson's disease [abstract]. Ann Neurol 1993; 34: 303
133. Haegele KD, Huebert ND, Myllyla V, et al. (E)-4-Fluro-b-fluoroethylene benzene butanamine (MDL 72974 A), an MAO-B inhibitor with potential for the treatment of Parkinson's disease: pharmacokinetics, selectivity and effects on neurotransmitters [abstract]. Clin Pharmacol Ther 1993; 53: 180
134. Allain H, Cougnard J, Neukirch HC. Selegiline in de novo parkinsonian patients: the French selegiline multicenter trial (FSMT). Acta Neurol Scand 1991; 84 Suppl. 136: 73-8
135. Myllyla VV, Sotaniemi KA, Vuorinen JA, et al. Selegiline as initial treatment in de novo parkinsonian patients. Neurology 1992; 42: 339-43
136. The Italian Parkinson Study Group. A multicenter Italian randomised study on early treatment of Parkinson's disease: comparison of l-dopa, l-deprenyl and dopaminoagonists. Study design and short term results. Ital J Neurol Sci 1992; 13: 735-9
137. Ziv I, Achiron A, Djaldetti R, et al. Short-term beneficial effect of deprenyl monotherapy in early Parkinson's disease: a quantitative assessment. Clin Neuropharmacol 1993; 16: 54-60
138. Shults CN, Parkinson Study Group. Effect of selegiline (deprenyl) on the progression of disability in early Parkinson's disease. Acta Neurol Scand 1993; 87 Suppl. 146: 36-42
139. Parkinson's Disease Research Group of the United Kingdom. Comparisons of therapeutic effects of levodopa, levodopa and selegiline, and bromocriptine in patients with early, mild Parkinson's disease: three year interim report. BMJ 1993; 307: 469-72
140. Lees AJ, Parkinson's Disease Research Group of the United Kingdom. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early mild Parkinson's disease. BMJ 1995; 311: 1602-7
141. Allain H, Bellissant E, Chaperon J, et al. Levodopa seule ou levodopa associe à la sélégiline dans le traitement de la maladie de Parkinson. Les resultats britanniques. Lett Pharmacol 1996; 10: 96-8
142. Nappi G, Martignoni E, Horowski R, et al. Lisuride plus selegiline in the treatment of early Parkinson's disease. Acta Neurol Scand 1991; 83: 407-10
143. Lander CM, Lees A, Stern G. Oscillations in performance in levodopa-treated parkinsonians: treatment with bromocriptine and L-deprenyl. Clin Exp Neurol 1979; 16: 197-203
144. Rinne UK, Siirtola T, Sonninen V. L-deprenyl effect of on-off phenomena in Parkinson's disease. J Neural Transm 1978; 43: 253-62
145. Cedarbaum JM, Toy LH, Green-Parsons A. L-Deprenyl (selegiline) added to Sinemet CR in the management of Parkinson's disease patients with motor response fluctuations. Clin Neuropharmacol 1991; 14: 228-34
146. Cedarbaum JM, Silvestri M, Clark M, et al. L-Deprenyl, levodopa pharmacokinetics, and response fluctuations in Parkinson's disease. Clin Neuropharmacol 1990; 13: 29-35
147. Golbe LI, Lieberman AN, Muenter MD, et al. Deprenyl in the treatment of symptom fluctuations in advanced Parkinson's disease. Clin Neuropharmacol 1988; II: 45-55
148. Lieberman A. Long term experience with selegiline and levodopa in Parkinson's disease. Neurology 1992; 42 Suppl. 4: 32-6
149. Parkinson Study Group. A controlled trial of lazabemide (RO 196327) in levodopa-treated Parkinson's disease. Arch Neurol 1994; 51: 342-7
150. Giuffra ME, Sethy VH, Davis TL, et al. Milacemide therapy for Parkinson's disease. Mov Disord 1993; 8: 47-50
151. Allain H, Lieury A, Thomas V, et al. Explicit and procedural memory in Parkinson's disease. Biomed Pharmacother 1995; 49: 179-86
152. Kieburtz K, McDermott M, Como P, et al. The effect of deprenyl and tocopherol on cognitive performance in early untreated Parkinson's disease. Neurology 1994; 44: 1756-9
153. Lees AJ. Selegiline hydrochloride and cognition. Acta Neurol Scand 1991; 84 Suppl. 136: 91-4
154. Hietanen MH. Selegiline and cognitive function in Parkinson's disease. Acta Neurol Scand 1991; 84: 407-10
155. Mac Entee WJ, Crook TH. Age-associated memory impairment: a role for catecholamines. Neurology 1990; 40: 526-30
156. Tariot PN, Cohen RM, Sunderland T, et al. L-deprenyl in Alzheimer's disease: preliminary evidence for behavioural change with monoamine oxidase B inhibition. Arch Gen Psychiatry 1987; 44: 427-33
157. Piccinin GL, Finali G, Piccirilli M. Neuropsychological effects of L-deprenyl in Alzheimer's type dementia. Clin Neuropharmacol 1990; 13: 147-63
158. Finali G, Piccirilli M, Oliani C, et al. L-deprenyl therapy improves verbal memory in amnesic Alzheimer patients. Clin Neuropharmacol 1991; 14: 523-36
159. Piccirilli FG, Oliani C, Piccinin GL. Alzheimer type dementia and verbal memory performances: influence of selegiline therapy. Ital J Neurol Sci 1992; 13: 141-8
160. Agnoli A, Fabbrini G, Fioravanti M, et al. CBF and cognitive evaluation of Alzheimer type patients before and after IMAO-B treatment: a pilot study. Eur Neuropsychopharmacol 1992; 2: 31-5
161. Goad DL, Davis CM, Liem P, et al. The use of selegiline in Alzheimer's patients with behavior problems. J Clin Psychiatry 1991; 52: 342-5
162. Wiseman LR, McTavish D. Selegiline: a review of its clinical efficacy in Parkinson's disease and its clinical potential in Alzheimer's disease. CNS Drugs 1995; 4 (3): 230-46
163. Muller WE, Scheuer K, Stoll S. Glutamatergic treatment strategies for age-related memory disorders. Life Sci 1994; 55: 2147-53
164. Herting RL. Milacemide and other drugs active at glutamate NMDA receptors as potential treatment for dementia. Ann NY Acad Sci 1991; 640: 237-40
165. Schwartz BL, Hashtroudi S, Herting RL, et al. Glycine prodrug facililates memory retrieval in humans. Neurology 1991; 41: 1341-3
166. Schwartz BL, Hashtroudi S, Herting RL, et al. The effects of milacemide on item and source memory. Clin Neuropharmcol 1992; 155: 114-9
167. Camp-Bruno JA, Herting RL. Cognitive effects of milacemide and methylphenidate in healthy young adults. Psychopharmacology 1994; 115: 46-52
168. Cutler NR, Fakouhi TD, Smith NT, et al. Evaluation of multiple doses of milacemide in the treatment of senile dementia of the Alzheimer's type. J Geriatr Psychiatry Neurol 1993; 6: 115-9
169. Dysken NW, Mendel SJ, Lewitt P, et al. Milacemide: a placebo controlled study in senile dementia of the Alzheimer type. J Am Geriatr Sc 1992; 40: 503-6
170. Cunningham LA. Depression in the medically ill: choosing an antidepressant. J Clin Psychiatry 1994; 55 Suppl. A: 90-7
171. Hublin C, Partinen M, Heinonen EH, et al. Selegiline in the treatment of narcolepsy. Neurology 1994; 44: 2095-101
172. Mayer G, Meier-Ewert K. Selegiline: a reversible MAO-B inhibitor in the treatment of narcolepsy [abstract]. J Sleep Res 1994; 3 Suppl. 1: 162
173. Jossan SS, Ekblom S, Gudjonsson O, et al. Double blind cross over trial with deprenyl in amyotrophic lateral sclerosis. J Neural Transm Suppl. 1994; 41: 237-41
174. O'Brien EM, Dostert PH, Pevarello P, et al. Interactions of some analogues or the anticonvulsant milacemide with monoamine oxidase. Biochem Pharmacol 1994; 48: 905-14
175. Vermersch P, Petit H. Tolérance de la selegiline au long cours dans le traitement de la maladie de Parkinson. Thérapie 1992; 47: 75-8
176. Heinonen EH, Rinne UK. Selegiline in the treatment of Parkinson's disease. Acta Neurol Scand 1989; 126: 103-11
177. Coleman RJ. Current drug therapy for Parkinson's disease: a review. Drugs Aging 1992; 2: 112-24
178. Myllyla UV, Sotaniemi KA, Vuorinen JA, et al. Selegiline in de novo Parkinsonian patients: the Finnish study. Mov Disord 1993; 8: S41-4
179. Vezina P, Mohr E, Grimes D. Deprenyl in Parkinson's disease: mechanisms, neuroprotective effect, indications and adverse effects. Can J Neurol Sci 1992; 19: 142-6
180. Koller WC, Giron LT. Selegiline HCl: selective MAO-type B inhibitor. Neurology 1990; 40: 58-60
181. Harrision WM, McGrath PJ, Siewart JW, et al. MAOIs and hypertensive crises: the role of OTC drugs. J Clin Psychiatry 1989; 50: 64-5
182. Tervainen H. Selegiline in Parkinson's disease. Acta Neurol Scand 1990; 81: 333-6
183. McGrath PJ, Stewart JW, Harrison W, et al. A placebo controlled trial of L-deprenyl in atypical depression. Psychopharmacol Bull 1989; 25: 63-7
184. Robertson DR, George CF. Adverse effects and long term problems of antiparkinsonian therapy. Adverse Drug React Bull 1990; 145: 544-7
185. Mangoni A, Grassi MP, Fratolla L, et al. Effects of a MAO-B inhibitor in the treatment of Alzheimer's disease. Eur Neurol 1991; 31: 100-7
186. Suchowersky O, Devries J. Possible interactions between deprenyl and Prozac [letter]. Can J Neurol Sci 1990; 17: 352-3
187. Montastruc JL, Chamontin B, Senard JM, et al. Pseudophaechromocytoma in parkinsonian patient treated with fluoxetine plus selegiline [letter]. Lancet 1993; 341: 555
188. Bryson HM, Milne RJ, Chrisp P. Selegiline: an appraisal of the basis of its pharmacoeconomic and quality of life benefits in Parkinson's disease. PharmacoEconomics 1992; 2: 118-36
189. Knopman D. Tacrine for Alzheimer's disease: costs and benefits. PharmacoEeonomics 1995; 7: 275-9